Featured Articles

1. Where Formulation Expertise Connects 5/20/2026

   As pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk. 

2. Safeguarding Biologic Quality And Performance 5/19/2026

   A science‑driven roadmap, from QTPP to QbD and phase‑appropriate strategies, helps ensure biologics stability, manufacturability, and a smooth path to successful commercialization

3. Enhancing Biologics Developability With Predictive In Silico Modelling 5/19/2026

   Predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

4. Advancing Formulation Strategies for Complex Drug Products 4/30/2026

   An event-focused overview examining how formulation development and stability strategies support robust, scalable drug products discussed at the DDF Summit Berlin.

5. Strengthening Drug Product CMC through Drug Product Science | AAPS 4/27/2026

   At AAPS, drug product experts discuss how formulation, stability, and analytical services enable robust CMC strategies, reduce development risk, and support confident regulatory decision‑making.

6. Managing CMC Risk For Complex Peptide And Nucleic Acid Therapeutics 4/24/2026

   At TIDES USA 2026, experts discuss how formulation science, stability strategies, and advanced analytics help reduce CMC risk and enable confident development of peptide and nucleic acid therapeutics.

7. Derisking And Accelerating Drug Development With Expertise 1/22/2026

   Scientific expertise and tailored development approaches reduce risk, boost stability and manufacturability, and accelerate drug programs toward commercialization.

8. Developability And Pre‑Formulation For A Faster Path To Approval 1/22/2026

   Developability and pre‑formulation screening uncover risks, inform molecule selection, and shorten development to reduce failures and accelerate approval.

9. Mitigating Risk In IND And Drug Product Development 1/22/2026

   Early CMC planning, a focus on manufacturability, and timely data generation help drug candidates cross the Valley of Death by reducing regulatory risk and easing clinical transition.

10. Overcoming Commercialization Challenges: Development Strategies 1/22/2026

    Late‑stage drug development requires optimized formulation, process characterization, packaging selection, and stability testing to ensure quality, compliance, and manufacturability.